$134.46 Million in Sales Anticipated for Medidata Solutions Inc (MDSO) This Quarter

$134.46 Million in Sales Anticipated for Medidata Solutions Inc (MDSO) This Quarter

Equities analysts expect Medidata Solutions Inc (NASDAQ:MDSO) to announce sales of $134.46 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Medidata Solutions’ earnings. The highest sales estimate is $135.20 million and the lowest is $133.90 million. Medidata Solutions posted sales of $114.61 million during the same quarter last year, which would indicate a positive year over year growth rate of 17.3%. The company is scheduled to report its next quarterly earnings results on Wednesday, July 19th.

According to Zacks, analysts expect that Medidata Solutions will report full year sales of $134.46 million for the current fiscal year, with estimates ranging from $549.57 million to $560.00 million. For the next year, analysts anticipate that the business will report sales of $651.12 million per share, with estimates ranging from $635.77 million to $667.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Medidata Solutions.

Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings results on Wednesday, April 26th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.20. The business had revenue of $126.80 million for the quarter, compared to analysts’ expectations of $125.90 million. Medidata Solutions had a return on equity of 10.82% and a net margin of 6.25%. The business’s quarterly revenue was up 21.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.25 EPS.

A number of equities research analysts have weighed in on MDSO shares. Jefferies Group LLC lifted their price objective on Medidata Solutions to $47.00 in a report on Friday, February 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $65.00 price objective on shares of Medidata Solutions in a report on Wednesday, April 19th. SunTrust Banks, Inc. raised Medidata Solutions from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $60.00 to $70.00 in a report on Friday, February 10th. Zacks Investment Research downgraded Medidata Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, May 17th. Finally, Piper Jaffray Companies lifted their price objective on Medidata Solutions from $60.00 to $72.00 and gave the company an “overweight” rating in a report on Tuesday, April 11th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $67.67.

Shares of Medidata Solutions (MDSO) traded up 0.97% during mid-day trading on Thursday, hitting $73.90. The stock had a trading volume of 355,119 shares. The stock has a market cap of $4.16 billion, a price-to-earnings ratio of 125.47 and a beta of 1.61. The firm has a 50 day moving average of $68.06 and a 200 day moving average of $57.63. Medidata Solutions has a one year low of $41.65 and a one year high of $74.32.

In other news, President Vries Glen Michael De sold 7,500 shares of Medidata Solutions stock in a transaction that occurred on Thursday, March 9th. The shares were sold at an average price of $56.05, for a total value of $420,375.00. Following the completion of the transaction, the president now owns 934,929 shares in the company, valued at $52,402,770.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael L. Capone sold 5,000 shares of Medidata Solutions stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $69.46, for a total transaction of $347,300.00. Following the completion of the transaction, the chief operating officer now owns 171,754 shares of the company’s stock, valued at approximately $11,930,032.84. The disclosure for this sale can be found here. Insiders sold 22,964 shares of company stock valued at $1,434,785 in the last quarter. 6.70% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of MDSO. Acrospire Investment Management LLC purchased a new position in Medidata Solutions during the first quarter worth about $121,000. Tyers Asset Management LLC purchased a new position in Medidata Solutions during the fourth quarter worth about $131,000. Flinton Capital Management LLC purchased a new position in Medidata Solutions during the fourth quarter worth about $159,000. LS Investment Advisors LLC boosted its position in Medidata Solutions by 44.6% in the first quarter. LS Investment Advisors LLC now owns 3,310 shares of the company’s stock worth $191,000 after buying an additional 1,021 shares during the period. Finally, Pacer Advisors Inc. purchased a new position in Medidata Solutions during the third quarter worth about $191,000. Institutional investors own 99.63% of the company’s stock.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:MDSO”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment